A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Coherent Biopharma (Hefei) Co., Ltd.
Institut Paoli-Calmettes
Centre Hospitalier Universitaire Vaudois
Universitair Ziekenhuis Brussel
Kaiser Permanente
Centre Leon Berard
University Hospital, Ghent
Uppsala University
Massachusetts General Hospital
Minneamrita Therapeutics LLC
Lebanese University
Fondazione per la Medicina Personalizzata
Immix Biopharma, Inc.
Massachusetts General Hospital
Amsterdam UMC, location VUmc
Kineta Inc.
Namida Lab
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shanghai Yunying Medical Technology
Shanghai Yunying Medical Technology
University of Calgary
Chongqing Precision Biotech Co., Ltd
MiRXES Pte Ltd
Jules Bordet Institute
Impact Therapeutics, Inc.
Genzada Pharmaceuticals USA, Inc.
Karolinska University Hospital
Provectus Pharmaceuticals
ImmVira Pharma Co. Ltd
Blue Note Therapeutics
Moscow Clinical Scientific Center
Main Line Health
Assistance Publique - Hôpitaux de Paris
Weprom
University of Kansas Medical Center
Charite University, Berlin, Germany
University of Florence
Peking University Cancer Hospital & Institute
SpeciCare
Instituto Portugues de Oncologia, Francisco Gentil, Porto
Rhode Island Hospital
Chinese University of Hong Kong
MetiMedi Pharmaceuticals
Sun Yat-sen University
Shenzhen Geno-Immune Medical Institute
Petra Pharma
Universidad Complutense de Madrid
Proteus Digital Health, Inc.
The First Affiliated Hospital of Dalian Medical University
Samyang Biopharmaceuticals Corporation